Annual report pursuant to Section 13 and 15(d)

Business (Tables)

v3.21.2
Business (Tables)
12 Months Ended
Jun. 30, 2021
Schedule Of Entities In Control [Abstract]  
Summary of entities in control
The consolidated financial statements of Benitec Biopharma Inc. are presented in United States dollars and consist of Benitec Biopharma Inc. and the following wholly owned subsidiaries:
 
 
  
Principal place of
business/country of
incorporation
Benitec Biopharma Proprietary Limited (“BBL”)
  
Australia
Benitec Australia Proprietary Limited
  
Australia
Benitec Limited
  
United Kingdom
Benitec, Inc.
  
USA
Benitec LLC
  
USA
RNAi Therapeutics, Inc.
  
USA
Tacere Therapeutics, Inc.
  
USA
Benitec IP Holdings, Inc.
  
USA